Patents Assigned to IMMUGEN PHARMA LLC
  • Non-hormonal treatment of the genitourinary syndrome of menopause
    Patent number: 11033527
    Abstract: Methods of treating the genitourinary syndrome of menopause (GSM) and modulating expression of genes involved in the GSM in an individual include administering compound L759,633 or compound JWH-133, both selective ligands for the endocannabinoid receptor type 2 (CB2). These compounds and compositions containing these compounds can be used as a non-hormonal alternative to hormones such as estrogen and ospemiphene for the treatment of the GSM and in particular, vaginal atrophy (VVA).
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: June 15, 2021
    Assignee: IMMUGEN PHARMA LLC
    Inventor: Craig R. Travis
  • NON-HORMONAL TREATMENT OF THE GENITOURINARY SYNDROME OF MENOPAUSE
    Publication number: 20190240190
    Abstract: Methods of treating the genitourinary syndrome of menopause (GSM) and modulating expression of genes involved in the GSM in an individual include administering compound L759,633 or compound JWH-133, both selective ligands for the endocannabinoid receptor type 2 (CB2). These compounds and compositions containing these compounds can be used as a non-hormonal alternative to hormones such as estrogen and ospemiphene for the treatment of the GSM and in particular, vaginal atrophy (VVA).
    Type: Application
    Filed: February 7, 2019
    Publication date: August 8, 2019
    Applicant: IMMUGEN PHARMA LLC
    Inventor: Craig R. Travis